Intravitreales bevacizumab bei der neovaskulären altersabhängigen makuladegeneration

M. S. Ladewig; F. Ziemssen; G. Jaissle; H. M. Helb; H. P.N. Scholl; N. Eter; K. U. Bartz-Schmidt; F. G. Holz

doi:10.1007/s00347-006-1352-5

Intravitreales bevacizumab bei der neovaskulären altersabhängigen makuladegeneration

Translated title of the contribution: Intravitreal bevacizumab for neovascular age-related macular degeneration

M. S. Ladewig, F. Ziemssen, G. Jaissle, H. M. Helb, H. P.N. Scholl, N. Eter, K. U. Bartz-Schmidt, F. G. Holz

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

The efficacy and safety of the therapeutic anti-VEGF concept has already been demonstrated for pegaptanib and ranibizumab. Bevacizumab acts as an antibody against all VEGF-A isoforms and has been developed for oncological indications with intravenous application. Initial reports on intravitreal administration in patients with neovascular age-related macular disease (AMD) have shown beneficial morphological and functional effects. In the meantime, bevacizumab has been used off-label in thousands of patients with AMD. However, data from prospective, controlled, randomized trials on both safety and efficacy are lacking. Herein recent experiences with bevacizumab are summarized and discussed. Furthermore, a web-based platform for online data registration and pooled analyses is presented.

Translated title of the contribution	Intravitreal bevacizumab for neovascular age-related macular degeneration
Original language	German
Pages (from-to)	463-470
Number of pages	8
Journal	Ophthalmologe
Volume	103
Issue number	6
DOIs	https://doi.org/10.1007/s00347-006-1352-5
State	Published - Jun 2006

Keywords

Age-related macular degeneration (ARMD)
Anti-VEGF therapy
Antiangiogenesis
Bevacizumab
Choroidal neovascularization (CNV)
Pegaptanib
Ranibizumab

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1007/s00347-006-1352-5

Cite this

@article{119da20d456c40f1a63a6ca6d1760c46,

title = "Intravitreales bevacizumab bei der neovaskul{\"a}ren altersabh{\"a}ngigen makuladegeneration",

abstract = "The efficacy and safety of the therapeutic anti-VEGF concept has already been demonstrated for pegaptanib and ranibizumab. Bevacizumab acts as an antibody against all VEGF-A isoforms and has been developed for oncological indications with intravenous application. Initial reports on intravitreal administration in patients with neovascular age-related macular disease (AMD) have shown beneficial morphological and functional effects. In the meantime, bevacizumab has been used off-label in thousands of patients with AMD. However, data from prospective, controlled, randomized trials on both safety and efficacy are lacking. Herein recent experiences with bevacizumab are summarized and discussed. Furthermore, a web-based platform for online data registration and pooled analyses is presented.",

keywords = "Age-related macular degeneration (ARMD), Anti-VEGF therapy, Antiangiogenesis, Bevacizumab, Choroidal neovascularization (CNV), Pegaptanib, Ranibizumab",

author = "Ladewig, {M. S.} and F. Ziemssen and G. Jaissle and Helb, {H. M.} and Scholl, {H. P.N.} and N. Eter and Bartz-Schmidt, {K. U.} and Holz, {F. G.}",

year = "2006",

month = jun,

doi = "10.1007/s00347-006-1352-5",

language = "German",

volume = "103",

pages = "463--470",

journal = "Fortschritte der Ophthalmologie : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft",

issn = "0941-293X",

publisher = "Springer Verlag",

number = "6",

}

TY - JOUR

T1 - Intravitreales bevacizumab bei der neovaskulären altersabhängigen makuladegeneration

AU - Ladewig, M. S.

AU - Ziemssen, F.

AU - Jaissle, G.

AU - Helb, H. M.

AU - Scholl, H. P.N.

AU - Eter, N.

AU - Bartz-Schmidt, K. U.

AU - Holz, F. G.

PY - 2006/6

Y1 - 2006/6

N2 - The efficacy and safety of the therapeutic anti-VEGF concept has already been demonstrated for pegaptanib and ranibizumab. Bevacizumab acts as an antibody against all VEGF-A isoforms and has been developed for oncological indications with intravenous application. Initial reports on intravitreal administration in patients with neovascular age-related macular disease (AMD) have shown beneficial morphological and functional effects. In the meantime, bevacizumab has been used off-label in thousands of patients with AMD. However, data from prospective, controlled, randomized trials on both safety and efficacy are lacking. Herein recent experiences with bevacizumab are summarized and discussed. Furthermore, a web-based platform for online data registration and pooled analyses is presented.

AB - The efficacy and safety of the therapeutic anti-VEGF concept has already been demonstrated for pegaptanib and ranibizumab. Bevacizumab acts as an antibody against all VEGF-A isoforms and has been developed for oncological indications with intravenous application. Initial reports on intravitreal administration in patients with neovascular age-related macular disease (AMD) have shown beneficial morphological and functional effects. In the meantime, bevacizumab has been used off-label in thousands of patients with AMD. However, data from prospective, controlled, randomized trials on both safety and efficacy are lacking. Herein recent experiences with bevacizumab are summarized and discussed. Furthermore, a web-based platform for online data registration and pooled analyses is presented.

KW - Age-related macular degeneration (ARMD)

KW - Anti-VEGF therapy

KW - Antiangiogenesis

KW - Bevacizumab

KW - Choroidal neovascularization (CNV)

KW - Pegaptanib

KW - Ranibizumab

UR - http://www.scopus.com/inward/record.url?scp=33745144003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745144003&partnerID=8YFLogxK

U2 - 10.1007/s00347-006-1352-5

DO - 10.1007/s00347-006-1352-5

M3 - Review article

C2 - 16763862

AN - SCOPUS:33745144003

VL - 103

SP - 463

EP - 470

JO - Fortschritte der Ophthalmologie : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft

JF - Fortschritte der Ophthalmologie : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft

SN - 0941-293X

IS - 6

ER -

Intravitreales bevacizumab bei der neovaskulären altersabhängigen makuladegeneration

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this